GlassScriptPhysician profile
Charles P Werner
NPI 1861584476
$224.30
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.34 · 2020: $43.82 · 2021: $130 · 2022: $25.79.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $50.99 | 2021 | |
| Pfizer INC. | $36.59 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $36.31 | 2021 | |
| Abbvie INC. | $30.78 | 2021-2022 | |
| Lilly USA, LLC | $28.22 | 2020-2021 | |
| Boston Scientific Corporation | $15.75 | 2020 | |
| Mylan Specialty L.P. | $13.07 | 2022 | |
| Astellas Pharma US INC | $12.59 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Werner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.